Septic shock with microcirculation dysfunction
Conditions
Interventions
Placebo-Control Group:Normal Saline
the experimental group:Penehyclidine Hydrochloride
Sponsors
Hunan Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The participants in this study are aged 18 or older. 2. The subjects met the diagnostic criteria for septic shock. Despite achieving the goals of macrocirculatory resuscitation following conventional treatment for septic shock, microcirculatory dysfunction persisted. 3. The participant or their family members provided written informed consent.
Exclusion criteria
Exclusion criteria: 1. The patient is under the age of 18. 2. Pregnant and breastfeeding women; 3. There is a documented case of allergy to penehyclidine hydrochloride or its constituents. 4. Patients with severe cardiovascular diseases (including heart failure classified as NYHA Class III or IV, myocardial infarction), significant arrhythmias that may lead to cardiogenic shock, acute or end-stage liver and kidney failure, hemorrhagic shock, advanced malignant tumors, glaucoma, and dysuria due to benign prostatic hyperplasia were excluded from the study. 5. The patient is experiencing severe septic shock, defined by the presence of any of the following criteria: 1) Persistent or refractory hypotension, characterized by a systolic blood pressure = 8 mmol/L; 3) Requirement for high-dose vasopressors (norepinephrine >= 0.5 µg/kg/min) to maintain blood pressure, or inability to achieve MAP >= 65 mmHg after adequate fluid resuscitation and vasopressor use; 4) Severe organ dysfunction, including but not limited to acute respiratory distress syndrome (ARDS), acute kidney injury (AKI) necessitating renal replacement therapy, acute liver failure, or hepatic encephalopathy. 6. The ISTH score is greater than or equal to five points. 7. Bedside B-ultrasound indicates the presence of severe peripheral artery disease, characterized by arterial lumen stenosis exceeding 50% or complete occlusion. 8. Received treatment with similar pharmacological agents (such as anticholinergic drugs including atropine and scopolamine) within the past week. 9. Patients who have participated in other clinical trials within the past 30 days. 10. Decline the standard therapeutic approach for septic shock; 11. The patient, along with their family members, declined to participate in this study. 12. The researchers posited that additional patients existed who were not suitable for study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peripheral Perfusion Index;Capillary Refill Time;Arterial Blood Lactate Levels; | — |
Secondary
| Measure | Time frame |
|---|---|
| Heart rate;SpO2; | — |
Countries
China
Contacts
Public ContactXiaotong Han
Hunan Provincial People's Hospital
Outcome results
None listed